Clinical trials: Splenectomy
Thrombocytopenia, Idiopathic Thrombocytopenic Purpura
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
The purpose of this study is to evaluate the efficacy of AMG 531 in the treatment of thrombocytopenia in subjects with ITP as measured by the platelet response.
- Trial name
- NCT00102323
- Testing
- AMG 531
- Volunteers
- 63 people
- Sponsor
- Amgen
Immune Thrombocytopenia (ITP)
A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)
The primary objective of this study was to assess the efficacy of 3 dose levels of lusutrombopag (0.5 mg, 0.75 mg, and 1.0 mg) and placebo on platelet count.
- Trial name
- NCT01054443
- Testing
- Lusutrombopag
- Where
- 19 sites in United States
- Volunteers
- 20 people
- Sponsor
- Shionogi
Liver Transplantation
A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation
The purpose of this study is to evaluate if treatment with a siplizumab-based regimen can induce allogeneic tolerance in liver transplant recipients.
- Trial name
- NCT06019507
- Testing
- TCD601, Cyclophosphamide, TAC
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- ITB-Med LLC
Idiopathic Thrombocytopenic Purpura
Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients
It is a phase III extension study to assess safety and immunogenicity of long-term therapy with GNR-069 in patients with idiopathic thrombocytopenic purpura
- Trial name
- NCT05492409
- Testing
- GNR-069
- Where
- 13 sites in Russia
- Volunteers
- 160 people
- Sponsor
- AO GENERIUM
Thrombocytopenia, Idiopathic Thrombocytopenic Purpura
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
The purpose of this study is to evaluate the efficacy of AMG 531 in the treatment of thrombocytopenia in subjects with ITP as measured by the platelet response.
- Trial name
- NCT00102336
- Testing
- AMG 531
- Volunteers
- 62 people
- Sponsor
- Amgen
Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic
Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
This is a Phase II/III multicenter study comprising of the double-blind, followed by open-label phases to evaluate and compare the efficacy and tolerability of eltrombopag (SB-497115-GR) in chronic ITP patients
- Trial name
- NCT00540423
- Testing
- SB-497115-GR 12.5mg, SB-497115-GR 25mg, SB-497115-GR 50 mg
- Where
- 7 sites in Japan
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Immune Thrombocytopenia
An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)
The primary objective of this study was to assess the long-term safety of lusutrombopag in the treatment of adults with relapsed persistent or chronic ITP with or without prior splenectomy.
- Trial name
- NCT01129024
- Testing
- Lusutrombopag
- Where
- 19 sites in United States
- Volunteers
- 19 people
- Sponsor
- Shionogi
Idiopathic Thrombocytopenic Purpura, Thrombocytopenia
Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
This is a phase 3b, multi-center, randomized, Standard of Care (SOC)-controlled, open-label, 52-week treatment study to compare romiplostim to medical SOC for Idiopathic Thrombocytopenia Purpura (ITP), with a 6-month Safety…
- Conditions
- Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenic Purpura
- Trial name
- NCT00415532
- Testing
- Medical Standard of Care for ITP, Romiplostim
- Volunteers
- 234 people
- Sponsor
- Amgen
Idiopathic Thrombocytopenic Purpura
Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP
It is a phase III multicenter randomized double-blinded comparative study of clinical efficacy and safety of GNR-069 and Nplate in patients with idiopathic thrombocytopenic purpura
- Trial name
- NCT05220878
- Testing
- GNR-069, Nplate
- Where
- 18 sites in Russia
- Volunteers
- 160 people
- Sponsor
- AO GENERIUM